A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and Acetaminophen

Evaluation of the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol HCl (75mg)/Acetaminophen (650mg) Extended Release Tablet: Multicenter, Open Label, Prospective, Observational Study

The purpose of this study is to evaluate the impact of extended release tramadol hydrochloride (75 mg) and acetaminophen (650 mg) tablets on improvement of pain.

Study Overview

• Status: Completed
• Conditions: Chronic Pain
• Intervention / Treatment: Drug: No intervention

Detailed Description

This is a multi-center (study conducted at multiple sites), open label (all people know the identity of the intervention), prospective (in which the participants are first identified and then followed forward as time passes), observational study to assess the improvement of pain and health-related quality of life in patients with moderate to severe chronic non-malignant pain. The study will enroll patients who had already filled a prescription for extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg (ULTRACET ER). The study medication will be administered according to local label insert. The study medication will be taken twice daily, 1 to 2 tablets each time, for a maximum of 4 tablets. Safety evaluations for adverse events will be performed throughout the study. The total duration of the study will be approximately of 12 weeks.

• Study Type: Observational
• Enrollment (Actual): 1065

Contacts and Locations

Study Locations

• Korea, Republic of
  • Busan, Korea, Republic of
  • Cheonan, Korea, Republic of
  • Chungcheongbuk-Do, Korea, Republic of
  • Chungju-Si, Korea, Republic of
  • Daegu, Korea, Republic of
  • Daejeon, Korea, Republic of
  • Goyang, Korea, Republic of
  • Gyeonggi-Do, Korea, Republic of
  • Hwasun Gun, Korea, Republic of
  • Kwangiu, Korea, Republic of
  • Kwangjoo, Korea, Republic of
  • Kyungjoo, Korea, Republic of
  • Seoul, Korea, Republic of
  • Suwon, Korea, Republic of

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with chronic non-malignant pain taking tramadol hydrochloride and acetaminophen

Description

Inclusion Criteria:

• Patients with the prescription of ULTRACET ER for the treatment of moderate to severe pain
• Complaining of chronic pain for more than 3 months

Exclusion Criteria:

• Patient who had been treated with extended release tramadol hydrochloride (75mg) and acetaminophen (650mg) or strong opioids (eg, morphine, fentanyl, oxycodone, hydromorphone) within the past 4 weeks
• Patient with a severe mental disease and with a medical history of hypersensitivity to opioid analgesics
• Pregnant females or the females likely to become pregnant during the study period
• Patient who had been believed likely to complain of more pain than the real pain he or she is experiencing because of industrial disaster, car insurance, and others
• Patients who are contraindicated according to the warnings, precautions and prohibitions regarding extended release tramadol hydrochloride (75mg) and acetaminophen (650mg)

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients taking tramadol hydrochloride and acetaminophen	Drug: No intervention; This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.; Other Names: ULTRACET ER

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with more than 30 percentage reduction in percentage Pain Intensity Difference (PID) from baseline	Numerical Rating Scale (NRS) is an 11-point scale to measure the pain intensity and is used by patients to rate their pain from 0 (absence of pain) to 10 (extreme pain). Percentage PID =[(NRS score at baseline - NRS score at Week 12)/NRS score at baseline] X 100.	Baseline (Week 1) to Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in scores of Korean version of the EuroQol 5 Dimensional (KEQ-5D) Questionnaire from baseline	The KEQ-5D is a validated generic measure of quality of life which usually requires less than 1 minute to complete (eg, the questionnaire may have questions about mobility, self care, usual activities, pain/discomfort and anxiety/depression).	Baseline to Week 12
The degree of night sleep disturbance due to pain	Sleep disturbance due to pain will be measured using a Numeric Rating Scale (NRS): 1 = None, 10 = Complete.	Baseline to Week 12
The degree of Interference with activity of daily living due to Pain	The degree of interference with activity of daily living due to pain will be assessed on a 5-point scale: 1 = No interference, 5 = Great interference. Activity of daily living means household work performance, etc.	Baseline to Week 12
The degree of Interference with social activities due to Pain	The degree of interference with social life performance due to pain will be measured on a 5-point scale; 1 = No interference, 5 = Great interference. Social activities means interpersonal relationship, going out, working life, etc.	Baseline to Week 12
The investigator's global assessment of pain treatment	The investigator will assess on a 5-point scale (1= not effective, 5= greatly effective) how effective the study drug has been for a patient, in the judgment of the investigator.	Week 4 to Week 12
The patient's global assessment of pain treatment	The patient will assess on a 5-point scale (1= not effective, 5= greatly effective) how effective the study drug has been in the judgment of the study patient.	Week 4 to Week 12
The number of patients who experience adverse events as a measure of safety and tolerability		Week 4 to Week 12

Collaborators and Investigators

• Sponsor: Janssen Korea, Ltd., Korea

Study record dates

Study Major Dates

• Study Start: September 1, 2011
• Primary Completion (Actual): July 1, 2012
• Study Completion (Actual): July 1, 2012

Study Registration Dates

• First Submitted: February 7, 2013
• First Submitted That Met QC Criteria: March 25, 2013
• First Posted (Estimate): March 28, 2013

Study Record Updates

• Last Update Posted (Estimate): January 1, 2015
• Last Update Submitted That Met QC Criteria: December 31, 2014
• Last Verified: December 1, 2014

More Information

Terms related to this study

• Keywords: Pain; Chronic pain; Acetaminophen; Chronic non-malignant pain; Non-malignant; Extended release tablet; Tramadol hydrochloride; Tramadol HCl; Ultracet ER
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Chronic Pain
• Other Study ID Numbers: CR100722; TRAMAPPAI4047 (Other Identifier: Janssen Korea, Ltd., Korea); ULTER-KOR-5005 (Other Identifier: Janssen Korea, Ltd., Korea)